AFfirm™ IL1 beta Mouse Monoclonal Antibody - #BF8021

>>买1送1 进行中>>
(14)   (7)  
产品: IL1 beta 小鼠 单克隆 抗体
货号: BF8021
描述: Mouse monoclonal antibody to IL1 beta
应用: WB IF/ICC
文献验证: WB
反应: Human, Mouse
蛋白号: P01584

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售
相关下载
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Mouse
应用:
WB 1:500-1:3000, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse
克隆:
Monoclonal [AFfirm8021]
特异性:
IL1 beta Antibody detects endogenous levels of total IL1 beta.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

Catabolin; H1; IL 1; IL 1 beta; IL-1 beta; IL1 BETA; IL1B; IL1B_HUMAN; IL1F2; Interleukin 1 beta; Interleukin-1 beta; OAF; OTTHUMP00000162031; Preinterleukin 1 beta; Pro interleukin 1 beta;

抗原和靶标

免疫原:

A synthesized peptide derived from human IL1 beta.

基因/基因ID:
IL1B(3553)

研究领域

· Cellular Processes > Cell growth and death > Necroptosis.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Environmental Information Processing > Signal transduction > NF-kappa B signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > Antifolate resistance.

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Human Diseases > Endocrine and metabolic diseases > Type I diabetes mellitus.

· Human Diseases > Neurodegenerative diseases > Alzheimer's disease.

· Human Diseases > Neurodegenerative diseases > Prion diseases.

· Human Diseases > Infectious diseases: Bacterial > Salmonella infection.

· Human Diseases > Infectious diseases: Bacterial > Pertussis.

· Human Diseases > Infectious diseases: Bacterial > Legionellosis.

· Human Diseases > Infectious diseases: Parasitic > Leishmaniasis.

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > African trypanosomiasis.

· Human Diseases > Infectious diseases: Parasitic > Malaria.

· Human Diseases > Infectious diseases: Parasitic > Amoebiasis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Immune diseases > Inflammatory bowel disease (IBD).

· Human Diseases > Immune diseases > Rheumatoid arthritis.

· Human Diseases > Immune diseases > Graft-versus-host disease.

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Cytosolic DNA-sensing pathway.   (View pathway)

· Organismal Systems > Immune system > Hematopoietic cell lineage.   (View pathway)

· Organismal Systems > Immune system > IL-17 signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Th17 cell differentiation.   (View pathway)

· Organismal Systems > Sensory system > Inflammatory mediator regulation of TRP channels.   (View pathway)

文献引用

1). Antibiotic cocktail-induced changes in gut microbiota drive alteration of bile acid metabolism to restrain Th17 differentiation through the FXR-NLRP3 axis. Gut microbes, 2025 (PubMed: 41305918) [IF=12.2]

Application: WB    Species: Mouse    Sample:

Figure 6. DCA initiates the NLRP3‒IL17A pathway to promote Th17 differentiation (A) Feeding schedule for EAP mice treated with ABX, ABX + DCA or ABX + DCA + MCC950. (B) Assessment of pelvic pain in mice using von Frey filaments. (C) H&E staining revealing alterations in prostate tissue. The red arrow indicates the invasion of inflammatory cells. Inflammation score assessment in the ABX, ABX + DCA and ABX + DCA + MCC950 groups. (D) Relative level of RORγt mRNA in prostate tissue from ABX, ABX + DCA and ABX + DCA + MCC950 mice. (E, F) The percentages of CD4+ IL-17A + and CD4+ RORγt + cells in the spleen of ABX, ABX + DCA and ABX + DCA + MCC950 mice. (G, H) Sorted naïve CD4+ T cells were activated for 5 days under Th17 cell differentiation conditions without DCA (media group), with DCA (media + DCA group) or with DCA + MCC950 (media + DCA + MCC950 group). Representative images and analysis of FCM staining for CD4+ IL-17A + cells and CD4+ RORγt + cells in the three groups. (I) Western blot analysis of NLRP3-IL17A-related proteins in the media, media + DCA, and media + DCA + MCC950 groups (n = 3). (J) IHC of NLRP3-IL17A-related proteins in prostate tissue from ABX, ABX + DCA and ABX + DCA + MCC950 mice. (K) ChIP‒qPCR was used to determine the binding status of FXR at three sites in the NLRP3 promoter. (L) Dual-luciferase assay showing the interaction between FXR and NLRP3. (n = 3–5; *, P 
2). A biomaterial-based therapy using a sodium hyaluronate/bioglass composite hydrogel for the treatment of oral submucous fibrosis. Acta Biomaterialia, 2023 (PubMed: 36509401) [IF=9.4]
3). Multi-omics analysis identified and confirmed TNF-α as a key initiator of the inflammatory response following spinal cord injury. International journal of biological macromolecules, 2025 (PubMed: 40319972) [IF=7.7]
4). Sophora moocroftiana seeds ethanol extract regulates NLRP3 inflammasome activation and pyroptosis via ROS/TXNIP pathway to amelioration of NAFLD in vitro and in vivo. Frontiers in pharmacology, 2025 (PubMed: 40926986) [IF=5.6]

Application: IHC    Species: Mouse    Sample:

Figure 5. Effect of SMS on TXNIP/NLRP3 pathway of pyroptosis in HFD-fed C57BL/6J mice. Snap frozen liver tissue sections of mice were analyzed by IHC for TXNIP, NLRP3, GSDMD and IL-1β and a representative image of mice per group has been displayed (200×). Silymarin (100 mg/kg) was used as the positive control.
5). HCMV-IE2 promotes atherosclerosis by inhibiting vascular smooth muscle cells' pyroptosis. Frontiers in microbiology, 2023 (PubMed: 37234524) [IF=5.2]
6). An integrated approach of experiment validation and single-cell RNA sequencing reveal dual-pathway inhibition of NLRP3/ferroptosis by flavonoids of Sanyeqing fibrous root in acute lung injury. Journal of ethnopharmacology, 2026 (PubMed: 41115482) [IF=4.8]

Application: WB    Species: Mouse    Sample:

Fig. 6. Effects of SYQfr-F on NLRP3 inflammasome expression in LPS-Induced ALI in vivo and in vitro. Western blot analysis of NLRP3, IL-1β, ASC, IL-18, and cleaved-caspase-1 protein expression in LPS-induced ALI in vivo (A–F). qRT-PCR analysis of NLRP3, IL-1β, ASC, IL-18, and caspase-1 mRNA expression in LPS-induced ALI in vivo (G–K). Western blot analysis of NLRP3, IL-1β, and ASC protein expression in LPS-induced ALI in vitro (L–O). (R–S) Immunofluorescence staining of NLRP3 and ASC in LPS-induced ALI in vitro. Fluorescence intensity analysis of ASC and cleaved-caspase-1 in LPS-induced ALI in vitro (P–Q).
7). Demethyleneberberine blocked the maturation of IL-1β in inflammation by inhibiting TLR4-mitochondria signaling. International Immunopharmacology, 2022 (PubMed: 36252484) [IF=4.8]
8). RBPMS2 can inhibit the NLRP3 / caspase-1 / GSDMD signaling pathway to resist pyroptosis in gastric cancer cells. Scientific reports, 2025 (PubMed: 40595708) [IF=3.8]
9). Ascorbic acid relieves neuropathic pain and depressive behavior by reducing inflammation and activating antioxidant responses. Molecular pain, 2025 (PubMed: 40616463) [IF=3.3]
10). Ursolic acid alleviates liver injury in diabetic mice induced by high-fat diet combined with streptozotocin via the NLRP3 signaling pathway. PloS one, 2026 (PubMed: 41637437) [IF=2.9]
加载更多

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.